TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6202967

Group type: COMPARATOR
Intervention: Verapamil (360 mg/day)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Verapamil (120 mg t.i.d.)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 11
Study: 31099911

Group type: EXPERIMENTAL
Intervention: Early glucocorticoid (GC) withdrawal
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chronic glucocorticoid (GC) treatment
Number of subjects: 0
Study: 29986928

Group type: EXPERIMENTAL
Intervention: MEP+ group (n=28)
Number of subjects: 61

Group type: COMPARATOR
Intervention: MEP- group (n=33)
Number of subjects: 61
Study: 27390369

Group type: EXPERIMENTAL
Intervention: ATZ/LNG 500 µg/20 µg (low dose)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: ATZ/LNG 1000 µg/30 µg (mid dose)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: ATZ/LNG 1500 µg/40 µg (high dose)
Number of subjects: 60
Study: 24275612

Group type: EXPERIMENTAL
Intervention: Individualised Stroop task
Number of subjects: 48

Group type: COMPARATOR
Intervention: General alcohol Stroop task
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control Stroop task (soft drink-related words)
Number of subjects: 48
Study: 21848509

Group type: EXPERIMENTAL
Intervention: Clark's Twin Block with upper labial bow (Group 1)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Clark's Twin Block without upper labial bow (Group 2)
Number of subjects: 62
Study: 19106732

Group type: EXPERIMENTAL
Intervention: EQ-5D index score (0.1 higher score)
Number of subjects: 7348
Study: 17897466

Group type: EXPERIMENTAL
Intervention: Intervention group (initially seronegative women)
Number of subjects: 1672

Group type: EXPERIMENTAL
Intervention: Intervention group (pregnant women)
Number of subjects: 1672
Study: 14532914

Group type: EXPERIMENTAL
Intervention: Amantadine 200 mg
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 11547542

Group type: EXPERIMENTAL
Intervention: 28% oxygen for the first 36 postoperative hours (treatment group, n = 13)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Room air (control group, n = 11)
Number of subjects: 24
Study: 9626884

Group type: EXPERIMENTAL
Intervention: Gadolinium (Gd) administered first in the same session (7 patients)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Ferumoxide administered first in the same session (3 patients)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Gadolinium administered in separate session (3 patients)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Gadolinium administered first in separate session (3 patients)
Number of subjects: 13
Study: 8179371

Group type: EXPERIMENTAL
Intervention: Epsilon-aminocaproic acid (5 g) before cardiopulmonary bypass
Number of subjects: 200

Group type: COMPARATOR
Intervention: Desmopressin alone (control group)
Number of subjects: 200
Study: 3067743

Group type: EXPERIMENTAL
Intervention: Trabeculectomy at diagnosis followed by supplementary medical therapy (group B)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Conventional medical treatment followed by trabeculectomy if unsuccessful (group A)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Trabeculectomy at diagnosis (group B)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Conventional medical treatment (group A)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 99
Study: 31277913

Group type: EXPERIMENTAL
Intervention: Proactive enteral nutrition (EN) via nasogastric (NG) feeding, commenced at 30 ml/h after stem cell infusion, increased to goal as oral intake declined.
Number of subjects: 44

Group type: COMPARATOR
Intervention: Standard care (parenteral nutrition, PN) commenced when oral intake was ≤60% of requirements for three days.
Number of subjects: 44
Study: 28826382

Group type: EXPERIMENTAL
Intervention: Culturally tailored, promotora‐facilitated 12‐week PA intervention
Number of subjects: 76
Study: 27497379

Group type: EXPERIMENTAL
Intervention: Antibiotic consumption (betalactams and amoxicillin)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 109

Group type: COMPARATOR
Intervention: Antibiotic consumption
Number of subjects: 109
Study: 24575737

Group type: EXPERIMENTAL
Intervention: Training dogs to discriminate prostate cancer urine samples from controls
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control samples (urine from men without prostate cancer)
Number of subjects: 10
Study: 23780505

Group type: EXPERIMENTAL
Intervention: Generic (test) formulation of betamethasone injectable suspension
Number of subjects: 24

Group type: COMPARATOR
Intervention: Branded (reference) formulation of betamethasone injectable suspension
Number of subjects: 24
Study: 20094043

Group type: EXPERIMENTAL
Intervention: pramlintide + sibutramine (10 mg q.a.m.)
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: pramlintide + phentermine (37.5 mg q.a.m.)
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: pramlintide (120 microg t.i.d.)
Number of subjects: 244

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: pramlintide + sibutramine
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: pramlintide + phentermine
Number of subjects: 244
Study: 18566793

Group type: EXPERIMENTAL
Intervention: Multimodal therapy including transurethral resection (TUR-B), open partial cystectomy, chemotherapy (intravesical or systemic), local radiation, and minimally invasive interventional therapies.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bladder sparing approaches (specific interventions not detailed).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conservative or less invasive treatment approaches (specific interventions not detailed).
Number of subjects: 0
Study: 16501948

Group type: EXPERIMENTAL
Intervention: Locally applied nasal decongestant agents: 2 drops twice/day of xylometazoline nasal solution 0.1% and 100microg budesonide (NDCA group, n=39)
Number of subjects: 79
Study: 12502488

Group type: EXPERIMENTAL
Intervention: Exogenous hyperinsulinemia
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Somatostatin infusion
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 15241837

Group type: EXPERIMENTAL
Intervention: Serum amyloid A (SAA)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Macrophage migration inhibitory factor (MIF)
Number of subjects: 50
Study: 10198296

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) 5, 12 units daily for 5 days
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) 1, 12 units for 1 day
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) treatment
Number of subjects: 28
Study: 7775175

Group type: EXPERIMENTAL
Intervention: 100% oxygen at 2 atmospheres of pressure (hyperbaric)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 100% oxygen at 1 atmosphere of pressure (normobaric)
Number of subjects: 20
Study: 2110271

Group type: EXPERIMENTAL
Intervention: 3.2 mg rt-PA
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: 6.4 mg rt-PA
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: 12.8 mg rt-PA
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: 25.6 mg rt-PA
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: 33.3 mg rt-PA
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: 50.0 mg rt-PA
Number of subjects: 186
Study: 552293

Group type: EXPERIMENTAL
Intervention: Lignocaine (oral administration)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lignocaine (intravenous administration)
Number of subjects: 12
Study: 30668211

Group type: EXPERIMENTAL
Intervention: Thumb taping for 4 weeks (Group A)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Thumb taping for 2 weeks (Group B)
Number of subjects: 20
Study: 28179230

Group type: EXPERIMENTAL
Intervention: Low dose computed tomography (CT) screening
Number of subjects: 5203
Study: 25791144

Group type: EXPERIMENTAL
Intervention: Group cognitive‐behavioral therapy (CBT) sessions (n = 45)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Waiting list control group (n = 44)
Number of subjects: 119
Study: 23714335

Group type: EXPERIMENTAL
Intervention: Endovascular coiling
Number of subjects: 1896

Group type: COMPARATOR
Intervention: Surgical clipping
Number of subjects: 1896
Study: 21233606

Group type: EXPERIMENTAL
Intervention: Steroids group (n = 105) - received 500 mg hydrocortisone immediately before hepatic‐pedicle clamping, followed by 300 mg on POD 1, 200 mg on POD 2, and 100 mg on POD 3
Number of subjects: 210

Group type: COMPARATOR
Intervention: Control group (n = 105)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Steroids group
Number of subjects: 210

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 210
Study: 20064183

Group type: EXPERIMENTAL
Intervention: Subdermal, pulsed, 1064‐nm Nd:YAG laser treatment
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combination of 1064‐nm Nd:YAG laser and removal of cell debris by suction cannula
Number of subjects: 20
Study: 17317751

Group type: EXPERIMENTAL
Intervention: SupEX (supine cycling at 60 r.p.m.)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 80EX (upright cycling at 80 r.p.m.)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (upright cycling at 60 r.p.m.)
Number of subjects: 8
Study: 15088864

Group type: EXPERIMENTAL
Intervention: 10 mg of diazepam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11259985

Group type: EXPERIMENTAL
Intervention: Chrysin (400 mg oral dose)
Number of subjects: 7
Study: 9498885

Group type: EXPERIMENTAL
Intervention: Patient-Controlled Epidural Administration (PCEA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Continuous Epidural Infusion
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 30
Study: 7893585

Group type: EXPERIMENTAL
Intervention: 125 mg BTS 67 582
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 250 mg BTS 67 582
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 500 mg BTS 67 582
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 2822795

Group type: EXPERIMENTAL
Intervention: ACTH (0.5 mg i.m; every 12 h)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Cortisol (50 mg orally, every 6 h)
Number of subjects: 6
Study: 31809408

Group type: EXPERIMENTAL
Intervention: 100 mg Tramadol
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 31099799

Group type: EXPERIMENTAL
Intervention: DVD education intervention and nurse teaching
Number of subjects: 54

Group type: COMPARATOR
Intervention: Nurse teaching
Number of subjects: 54
Study: 29028776

Group type: EXPERIMENTAL
Intervention: Western classical music
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Turkish classical music
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 96
Study: 25589191

Group type: EXPERIMENTAL
Intervention: Afatinib
Number of subjects: 709

Group type: COMPARATOR
Intervention: Pemetrexed-cisplatin (LUX-Lung 3)
Number of subjects: 709

Group type: COMPARATOR
Intervention: Gemcitabine-cisplatin (LUX-Lung 6)
Number of subjects: 709

Group type: EXPERIMENTAL
Intervention: Afatinib for del19-positive tumours
Number of subjects: 709

Group type: COMPARATOR
Intervention: Chemotherapy for del19-positive tumours
Number of subjects: 709

Group type: EXPERIMENTAL
Intervention: Afatinib for Leu858Arg-positive tumours
Number of subjects: 709

Group type: COMPARATOR
Intervention: Chemotherapy for Leu858Arg-positive tumours
Number of subjects: 709
Study: 22843347

Group type: EXPERIMENTAL
Intervention: LHA intervention with behavioral counseling and nicotine patches
Number of subjects: 147
Study: 20930640

Group type: EXPERIMENTAL
Intervention: Viral Suppression (VS) group
Number of subjects: 254

Group type: COMPARATOR
Intervention: Drug Conservation (DC) group
Number of subjects: 254
Study: 19299775

Group type: EXPERIMENTAL
Intervention: Subtenon block (SB) with 0.06-0.08 mL/kg of 2% lidocaine and 0.5% bupivacaine (50:50) mixture and simultaneous 0.2 mL/kg normal saline IV
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Subtenon block (SB)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Intravenous fentanyl (IV F) 1 microg/kg (0.2 mL/kg of 5 microg/kg)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Intravenous fentanyl (IV F)
Number of subjects: 114
Study: 17582921

Group type: EXPERIMENTAL
Intervention: Human papillomavirus vaccine (3-dose schedule: 0, 2, and 6 months)
Number of subjects: 18000

Group type: EXPERIMENTAL
Intervention: Human papillomavirus vaccine
Number of subjects: 18000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18000
Study: 15213043

Group type: EXPERIMENTAL
Intervention: 50 or 100 microg Se (as sodium selenite)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 12866806

Group type: EXPERIMENTAL
Intervention: Atenolol treatment
Number of subjects: 22
Study: 9797204

Group type: EXPERIMENTAL
Intervention: Ritonavir 200 mg q12h with indinavir 800 mg q8h
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Ritonavir 300 mg q12h with indinavir 600 mg q8h
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Ritonavir 300 mg q12h with indinavir 400 mg q8h
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Ritonavir 400 mg q12h with indinavir 400 mg q8h
Number of subjects: 5

Group type: COMPARATOR
Intervention: Indinavir 800 mg q8h (standard regimen)
Number of subjects: 5
Study: 8591964

Group type: EXPERIMENTAL
Intervention: Various treatment schemes including individualized therapy based on risk factors.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anthracycline treatment for stage III and IV favorable histology Wilms tumor.
Number of subjects: 0
Study: 2528405

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) infusion (0.25 to 12 micrograms.min‐1)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) infusion
Number of subjects: 6
Study: 349395

Group type: EXPERIMENTAL
Intervention: X-ray therapy (XRT)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: BCNU
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: BCNU + XRT
Number of subjects: 225

Group type: COMPARATOR
Intervention: Control treatment (no further treatment)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Age (young)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Symptoms of seizures
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Cranial nerve symptoms
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Encapsulated tumor
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Parietal tumor location
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Biopsy (operation biopsy only)
Number of subjects: 225
Study: 31980638

Group type: EXPERIMENTAL
Intervention: Short-acting nifedipine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Extended release nifedipine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31152598

Group type: EXPERIMENTAL
Intervention: Prolonged Release Tacrolimus
Number of subjects: 18

Group type: COMPARATOR
Intervention: Immediate Release Tacrolimus
Number of subjects: 18
Study: 28939406

Group type: EXPERIMENTAL
Intervention: Amlodipine/Losartan Potassium/Chlorthalidone (A/L/C)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Amlodipine/Losartan Potassium (A/L)
Number of subjects: 330
Study: 26154787

Group type: EXPERIMENTAL
Intervention: Guselkumab 5 mg
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Guselkumab 15 mg
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Guselkumab 50 mg
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Guselkumab 100 mg
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Guselkumab 200 mg
Number of subjects: 293

Group type: COMPARATOR
Intervention: Adalimumab
Number of subjects: 293

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Guselkumab (all doses)
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Infections
Number of subjects: 293
Study: 23471226

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided corticosteroid injection
Number of subjects: 42

Group type: COMPARATOR
Intervention: Full-length silicone insole
Number of subjects: 42
Study: 21194255

Group type: EXPERIMENTAL
Intervention: Autologous bone marrow-derived CD133(+) cells
Number of subjects: 6

Group type: COMPARATOR
Intervention: Autologous bone marrow-derived mononuclear cells
Number of subjects: 6
Study: 19103946

Group type: EXPERIMENTAL
Intervention: Moral reasoning exercise
Number of subjects: 2020

Group type: COMPARATOR
Intervention: No moral reasoning exercise (control group)
Number of subjects: 2020
Study: 16504646

Group type: EXPERIMENTAL
Intervention: Rimonabant 1 mg
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Rimonabant 3 mg
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Rimonabant 10 mg
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Rimonabant 30 mg
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Rimonabant 90 mg
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63

Group type: COMPARATOR
Intervention: Marijuana smoking (2.64% THC) after placebo rimonabant
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Rimonabant (any dose)
Number of subjects: 63
Study: 14687308

Group type: EXPERIMENTAL
Intervention: Experimental nutritional formula (8 oz/d) containing antioxidants, zinc, selenium, fermentable oligosaccharides, and structured triacylglycerol
Number of subjects: 66

Group type: COMPARATOR
Intervention: Isoenergetic, isonitrogenous control formula
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Experimental nutritional formula
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 66
Study: 11058714

Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg/day, n=24)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg/day, n=26)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both statins
Number of subjects: 50
Study: 9348449

Group type: EXPERIMENTAL
Intervention: Omafilcon A
Number of subjects: 30

Group type: COMPARATOR
Intervention: Etafilcon A
Number of subjects: 30

Group type: COMPARATOR
Intervention: Welcon CE
Number of subjects: 30
Study: 8406153

Group type: EXPERIMENTAL
Intervention: Elemental diet (Vivonex TEN 2.1 l/day for four weeks)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Prednisolone (0.75 mg/kg/day for two weeks and subsequent reducing doses)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Prednisolone
Number of subjects: 42

Group type: COMPARATOR
Intervention: Elemental diet
Number of subjects: 42
Study: 2426997

Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 446

Group type: COMPARATOR
Intervention: No Lidocaine (Control)
Number of subjects: 446
Study: 30661561

Group type: EXPERIMENTAL
Intervention: Exposure and response prevention (ERP) for OCD
Number of subjects: 90
Study: 28915080

Group type: EXPERIMENTAL
Intervention: 3.0 mg/kg reslizumab IV Q4W
Number of subjects: 10
Study: 26631986

Group type: EXPERIMENTAL
Intervention: 'PREPARED ON TIME' e-learning program
Number of subjects: 254

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 254
Study: 25193670

Group type: EXPERIMENTAL
Intervention: IRA occlusion in patients without diabetes
Number of subjects: 3046

Group type: EXPERIMENTAL
Intervention: IRA occlusion in patients with diabetes
Number of subjects: 3046

Group type: EXPERIMENTAL
Intervention: Baseline IRA occlusion in nondiabetic patients
Number of subjects: 3046

Group type: EXPERIMENTAL
Intervention: Baseline IRA occlusion in diabetic patients
Number of subjects: 3046
Study: 22395798

Group type: EXPERIMENTAL
Intervention: Migraine (any)
Number of subjects: 31370

Group type: EXPERIMENTAL
Intervention: Migraine with aura
Number of subjects: 31370

Group type: EXPERIMENTAL
Intervention: Migraine without aura
Number of subjects: 31370

Group type: EXPERIMENTAL
Intervention: New reports of migraine during follow‐up
Number of subjects: 31370

Group type: EXPERIMENTAL
Intervention: Prior migraine
Number of subjects: 31370
Study: 19447770

Group type: EXPERIMENTAL
Intervention: Rituximab (RTX) - two cycles at baseline and 24 weeks, each cycle consisting of four weekly infusions (375 mg/m²)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Standard treatment alone (Control)
Number of subjects: 14
Study: 17851890

Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy with carboplatin and uracil‐f tegafur (UFT)
Number of subjects: 62
Study: 15283063

Group type: EXPERIMENTAL
Intervention: Nonvisual walking
Number of subjects: 0
Study: 11152857

Group type: EXPERIMENTAL
Intervention: Primary stenting
Number of subjects: 88

Group type: COMPARATOR
Intervention: Angioplasty
Number of subjects: 88
Study: 9506636

Group type: EXPERIMENTAL
Intervention: High-frequency oscillatory ventilation (HFOV)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Intermittent positive pressure ventilation (IPPV)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Gas exchange and ventilator support
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Extraalveolar air
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Intracranial bleeding
Number of subjects: 96
Study: 7827642

Group type: EXPERIMENTAL
Intervention: Cyproterone acetate + estradiol valerate
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Cyproterone acetate + transdermal estradiol
Number of subjects: 67
Study: 2907735

Group type: EXPERIMENTAL
Intervention: 400 mg of glafenine twice a day
Number of subjects: 166

Group type: COMPARATOR
Intervention: 1000 mg of paracetamol twice a day
Number of subjects: 166
Study: 4880261

Group type: EXPERIMENTAL
Intervention: Tetramisole
Number of subjects: 200

Group type: COMPARATOR
Intervention: Piperazine
Number of subjects: 200
Study: 31112605

Group type: EXPERIMENTAL
Intervention: Conversation-based intervention (daily 30-min face-to-face semi-structured conversations with trained interviewers for 6 weeks)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Conversation-based intervention
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 83
Study: 29668354

Group type: EXPERIMENTAL
Intervention: Pulsed high-intensity laser therapy three times per week for 8 weeks, along with usual hormonal treatment
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham laser treatment three times per week for 8 weeks, along with usual hormonal treatment
Number of subjects: 40
Study: 27924462

Group type: EXPERIMENTAL
Intervention: Mujer Segura intervention
Number of subjects: 528